319 related articles for article (PubMed ID: 33587160)
1. Severe toxicity of capecitabine in a patient with DPD deficiency after a safe FEC-100 experience: why we should test DPD deficiency in all patients before high-dose fluoropyrimidines.
Maillard M; Eche-Gass A; Ung M; Brice A; Marsili S; Montastruc M; Puisset F; Thomas F
Cancer Chemother Pharmacol; 2021 Apr; 87(4):579-583. PubMed ID: 33587160
[TBL] [Abstract][Full Text] [Related]
2. [Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks].
Loriot MA; Ciccolini J; Thomas F; Barin-Le-Guellec C; Royer B; Milano G; Picard N; Becquemont L; Verstuyft C; Narjoz C; Schmitt A; Bobin-Dubigeon C; Harle A; Paci A; Poinsignon V; Quaranta S; Evrard A; Hennart B; Broly F; Fonrose X; Lafay-Chebassier C; Wozny AS; Masskouri F; Boyer JC; Etienne-Grimaldi MC
Bull Cancer; 2018 Apr; 105(4):397-407. PubMed ID: 29486921
[TBL] [Abstract][Full Text] [Related]
3. Lethal toxicities after capecitabine intake in a previously 5-FU-treated patient: why dose matters with dihydropryimidine dehydrogenase deficiency.
Gbeto CC; Quaranta S; Mari R; Fanciullino R; Roche C; Nahon S; Solas C; Ouafik L; Lacarelle B; Allegre T; Ciccolini J
Pharmacogenomics; 2019 Aug; 20(13):931-938. PubMed ID: 31486738
[TBL] [Abstract][Full Text] [Related]
4. Complete DPYD genotyping combined with dihydropyrimidine dehydrogenase phenotyping to prevent fluoropyrimidine toxicity: A retrospective study.
De Metz C; Hennart B; Aymes E; Cren PY; Martignène N; Penel N; Barthoulot M; Carnot A
Cancer Med; 2024 Mar; 13(6):e7066. PubMed ID: 38523525
[TBL] [Abstract][Full Text] [Related]
5. Capecitabine-based treatment of a patient with a novel DPYD genotype and complete dihydropyrimidine dehydrogenase deficiency.
Henricks LM; Siemerink EJM; Rosing H; Meijer J; Goorden SMI; Polstra AM; Zoetekouw L; Cats A; Schellens JHM; van Kuilenburg ABP
Int J Cancer; 2018 Jan; 142(2):424-430. PubMed ID: 28929491
[TBL] [Abstract][Full Text] [Related]
6. Severe fluoropyrimidine toxicity due to novel and rare DPYD missense mutations, deletion and genomic amplification affecting DPD activity and mRNA splicing.
van Kuilenburg AB; Meijer J; Maurer D; Dobritzsch D; Meinsma R; Los M; Knegt LC; Zoetekouw L; Jansen RL; Dezentjé V; van Huis-Tanja LH; van Kampen RJ; Hertz JM; Hennekam RC
Biochim Biophys Acta Mol Basis Dis; 2017 Mar; 1863(3):721-730. PubMed ID: 28024938
[TBL] [Abstract][Full Text] [Related]
7. Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines.
Meulendijks D; Henricks LM; van Kuilenburg AB; Jacobs BA; Aliev A; Rozeman L; Meijer J; Beijnen JH; de Graaf H; Cats A; Schellens JH
Cancer Chemother Pharmacol; 2016 Oct; 78(4):875-80. PubMed ID: 27544765
[TBL] [Abstract][Full Text] [Related]
8. Severe Gastrointestinal Disorder Due to Capecitabine Associated with Dihydropyrimidine Dehydrogenase Deficiency: A Case Report and Literature Review.
Hagiwara Y; Yamamoto Y; Inagaki Y; Tomisaki R; Tsuji M; Fukuda S; Fukuda S; Onoda T; Suzuki H; Niisato Y; Tange Y; Ikeda N; Yamada K; Kobayashi M; Akutsu D; Yamada T; Moriwaki T; Narasaka T; Suzuki H; Tsuchiya K
Intern Med; 2022 Aug; 61(16):2449-2455. PubMed ID: 35110482
[TBL] [Abstract][Full Text] [Related]
9. Joint Belgian recommendation on screening for DPD-deficiency in patients treated with 5-FU, capecitabine (and tegafur).
Casneuf V; Borbath I; Van den Eynde M; Verheezen Y; Demey W; Verstraete AG; Bm Claes K; Haufroid V; Geboes KP
Acta Clin Belg; 2022 Apr; 77(2):346-352. PubMed ID: 33423619
[TBL] [Abstract][Full Text] [Related]
10. Severe adverse events due to dihydropyrimidine dehydrogenase deficiency in a Japanese patient with colon cancer taking capecitabine: a case report.
Tsutsui M; Yamamoto S; Yoshikawa Y; Nakanishi R; Takano K; Osumi K; Akatsu T; Yoneyama K; Nakagawa M; Kanai T
Int Cancer Conf J; 2018 Oct; 7(4):125-129. PubMed ID: 31149530
[TBL] [Abstract][Full Text] [Related]
11. Awareness and attitudes of oncology specialists toward dihydropyrimidine dehydrogenase testing in Saudi Arabia.
Sukkarieh HH; AlSagoor T; Alnuhait M; Bustami R; Bryson S; Adem FMK; Abdalla H; Karbani G
Cancer Rep (Hoboken); 2023 Feb; 6(2):e1704. PubMed ID: 36806724
[TBL] [Abstract][Full Text] [Related]
12. [Dihydropyrimidine dehydrogenase deficiency causes severe adverse effects of capecitabine].
Inoue H; Sato Y; Shintani S; Tanabe H; Bamba H; Komai Y; Nakamura T; Imai T; Andou A
Nihon Shokakibyo Gakkai Zasshi; 2018; 115(3):290-298. PubMed ID: 29526981
[TBL] [Abstract][Full Text] [Related]
13. [Dihydropyrimidine dehydrogenase deficiency screening for management of patients receiving a fluoropyrimidine: Results of two national practice surveys addressed to clinicians and biologists].
Loriot MA; Masskouri F; Carni P; Le Malicot K; Seitz JF; Michel P; Legoux JL; Bouché O; André T; Faroux R; Delaloge S; Malka D; Guigay J; Thariat J; Thomas F; Barin-Le-Guellec C; Ciccolini J; Boyer JC; Étienne-Grimaldi MC
Bull Cancer; 2019 Sep; 106(9):759-775. PubMed ID: 31253356
[TBL] [Abstract][Full Text] [Related]
14. Is capecitabine safe in patients with gastrointestinal cancer and dihydropyrimidine dehydrogenase deficiency?
Saif MW; Diasio R
Clin Colorectal Cancer; 2006 Jan; 5(5):359-62. PubMed ID: 16512996
[TBL] [Abstract][Full Text] [Related]
15. Clinical implementation of pre-treatment DPYD genotyping in capecitabine-treated metastatic breast cancer patients.
Stavraka C; Pouptsis A; Okonta L; DeSouza K; Charlton P; Kapiris M; Marinaki A; Karapanagiotou E; Papadatos-Pastos D; Mansi J
Breast Cancer Res Treat; 2019 Jun; 175(2):511-517. PubMed ID: 30746637
[TBL] [Abstract][Full Text] [Related]
16. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines.
Lunenburg CATC; van der Wouden CH; Nijenhuis M; Crommentuijn-van Rhenen MH; de Boer-Veger NJ; Buunk AM; Houwink EJF; Mulder H; Rongen GA; van Schaik RHN; van der Weide J; Wilffert B; Deneer VHM; Swen JJ; Guchelaar HJ
Eur J Hum Genet; 2020 Apr; 28(4):508-517. PubMed ID: 31745289
[TBL] [Abstract][Full Text] [Related]
17. Impact of renal impairment on dihydropyrimidine dehydrogenase (DPD) phenotyping.
Royer B; Launay M; Ciccolini J; Derain L; Parant F; Thomas F; Guitton J
ESMO Open; 2023 Jun; 8(3):101577. PubMed ID: 37267808
[TBL] [Abstract][Full Text] [Related]
18. [A case in which dihydropyrimidine dehydrogenase deficiency was strongly suspected during adjuvant chemotherapy with capecitabine for colon cancer].
Toshima T; Kodera M; Yamashita Y; Oishi M; Seshimo K; Yamamura M; Kato H; Ikeda H; Mizuno K
Gan To Kagaku Ryoho; 2013 Nov; 40(11):1549-52. PubMed ID: 24231713
[TBL] [Abstract][Full Text] [Related]
19. DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY (DPD) IN GI MALIGNANCIES: EXPERIENCE OF 4-YEARS.
Saif MW; Syrigos K; Mehra R; Mattison LK; Diasio RB
Pak J Med Sci; 2007; 23(6):832-839. PubMed ID: 18846242
[TBL] [Abstract][Full Text] [Related]
20. Benefit of uridine triacetate (Vistogard) in rescuing severe 5-fluorouracil toxicity in patients with dihydropyrimidine dehydrogenase (DPYD) deficiency.
Saif MW; Diasio RB
Cancer Chemother Pharmacol; 2016 Jul; 78(1):151-6. PubMed ID: 27278667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]